Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) - Research analysts at Leerink Partnrs boosted their Q2 2025 earnings estimates for Trevi Therapeutics in a research note issued to investors on Wednesday, June 11th. Leerink Partnrs analyst F. Khurshid now forecasts that the company will earn ($0.08) per share for the quarter, up from their previous forecast of ($0.10). The consensus estimate for Trevi Therapeutics' current full-year earnings is ($0.49) per share. Leerink Partnrs also issued estimates for Trevi Therapeutics' Q3 2025 earnings at ($0.10) EPS, Q4 2025 earnings at ($0.11) EPS, FY2025 earnings at ($0.38) EPS and FY2026 earnings at ($0.39) EPS.
Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) last announced its earnings results on Tuesday, May 6th. The company reported ($0.09) earnings per share for the quarter, topping analysts' consensus estimates of ($0.13) by $0.04.
Other equities research analysts have also issued research reports about the company. HC Wainwright began coverage on Trevi Therapeutics in a research report on Wednesday, May 28th. They issued a "buy" rating and a $21.00 target price on the stock. Raymond James raised shares of Trevi Therapeutics from an "outperform" rating to a "strong-buy" rating and raised their price target for the stock from $9.00 to $29.00 in a research note on Monday, March 10th. B. Riley reiterated a "buy" rating and issued a $20.00 price objective (up from $11.00) on shares of Trevi Therapeutics in a report on Wednesday, March 19th. Oppenheimer reissued an "outperform" rating on shares of Trevi Therapeutics in a research report on Monday, June 2nd. Finally, Wall Street Zen downgraded shares of Trevi Therapeutics from a "hold" rating to a "sell" rating in a research report on Friday, June 6th. One research analyst has rated the stock with a sell rating, seven have assigned a buy rating and three have issued a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus target price of $18.63.
Check Out Our Latest Research Report on TRVI
Trevi Therapeutics Price Performance
Shares of TRVI traded down $0.08 during midday trading on Friday, hitting $6.09. The stock had a trading volume of 1,142,084 shares, compared to its average volume of 1,353,871. The firm has a market cap of $608.35 million, a price-to-earnings ratio of -13.84 and a beta of 0.59. The company has a 50 day simple moving average of $6.28 and a two-hundred day simple moving average of $5.08. Trevi Therapeutics has a twelve month low of $2.36 and a twelve month high of $7.48.
Insider Buying and Selling
In other Trevi Therapeutics news, CEO Jennifer L. Good sold 5,263 shares of the stock in a transaction on Friday, March 21st. The shares were sold at an average price of $6.58, for a total value of $34,630.54. Following the completion of the sale, the chief executive officer now owns 213,313 shares in the company, valued at $1,403,599.54. This trade represents a 2.41% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. 18.30% of the stock is owned by corporate insiders.
Institutional Investors Weigh In On Trevi Therapeutics
A number of institutional investors and hedge funds have recently modified their holdings of TRVI. Summit Investment Advisors Inc. increased its position in Trevi Therapeutics by 84.2% during the fourth quarter. Summit Investment Advisors Inc. now owns 6,332 shares of the company's stock worth $26,000 after buying an additional 2,894 shares during the last quarter. Raymond James Financial Inc. bought a new position in shares of Trevi Therapeutics during the 4th quarter worth approximately $49,000. Strs Ohio bought a new position in shares of Trevi Therapeutics during the 1st quarter worth approximately $52,000. Squarepoint Ops LLC acquired a new position in shares of Trevi Therapeutics during the 4th quarter worth approximately $58,000. Finally, Two Sigma Advisers LP acquired a new position in shares of Trevi Therapeutics during the 4th quarter worth approximately $66,000. 95.76% of the stock is owned by institutional investors.
Trevi Therapeutics Company Profile
(
Get Free Report)
Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.
Read More
Before you consider Trevi Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Trevi Therapeutics wasn't on the list.
While Trevi Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
